Navigation Links
Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
Date:6/25/2010

CAMBRIDGE, Mass., June 25 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression. Anti-GITR agents have been identified by the National Cancer Institute as having high potential for treating cancer.  The preclinical data were presented and recognized as a distinguished abstract at the annual meeting of the Federation of Clinical Immunology Societies in Boston, Massachusetts.

The data included in the presentation demonstrated that a murine analog of TRX518, which is an anti-GITR antibody, resulted in pronounced and durable immune responses to several antigens in mice. These data also showed that the TRX518 analog, when combined with gemcitabine, a standard chemotherapeutic, significantly reduced tumor burden (p<0.001) and prolonged survival (p<0.001) in the mouse model when compared with gemcitabine alone. In particular, of the mice treated with the combination therapy, 65% had a complete remission. Similar findings were observed when the TRX518 analog was combined with cyclophosphamide. The humanized monoclonal antibody, TRX518, blocked the interaction of GITR with its ligand, enhanced the cytotoxicity of human natural killer cells, downmodulated GITR on peripheral blood lympocytes, did not induce appreciable cytokine release, and was well tolerated and safe at high doses in non-human primates.

"We are highly encouraged by the preclinical results with anti-GITR immunotherapy. This approach appears to induce unique mechanisms for augmenting antitumor immune responses and holds promise for treating malignancies in man," said Louis Vaickus, MD, Chief Medical Officer at Tolerx. "In a murine model of established colon cancer, the results, especially the complete remissions, were striking and these findings represent preclinical proof of concept for TRX518."

About TRX518

TRX518 is a targeted T-cell immunomodulator that binds to the glucocorticoid-induced tumor necrosis factor receptor (GITR) found on multiple types of T cells and other immune cells. Activated GITR plays a role in directing the antitumor immune response via activating tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. In preclinical studies, TRX518 achieved its targeted effect without compromising normal immune function and preclinical models suggest TRX518 may have a reduced risk of causing the serious inflammatory side effects that can result from cytokine release.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has three preclinical candidates, TRX518, TRX585, and TRX385, which enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
2. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
10. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
11. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):